SPECIAL MEDICAL EDITORIAL
Antioxidant therapy for atherosclerotic vascular disease: the promise and the pitfalls

Departments of ¹ Internal Medicine and ² Biochemistry, University of Iowa College of Medicine, Iowa City, Iowa 52242

	INTRODUCTION

TOP INTRODUCTION DIFFERENCES BETWEEN IN VITRO... CELLULAR AND ENZYMATIC SOURCES... EFFECTS OF ROS ON... IMPORTANCE OF ROS AS... ADDITIONAL CONSIDERATIONS CONCLUSIONS REFERENCES

THE POTENTIAL VALUE OF ANTIOXIDANTS in treating conditions associated with oxidative stress is well known to scientists and clinicians and is of immense interest to patients. Oxidative stress is a term used to describe an imbalance between the production and destruction of reactive oxygen species (ROS), such as superoxide anions (O·) and hydrogen peroxide (H₂O₂), thereby leading to cellular and tissue injury. The basic properties of oxygen are responsible for the destructive power of free radicals, in particular, their high reactivity. Humans consume ~250 g of oxygen every day, and of this ~3-5% is converted to O· and other reactive species (38).

The damage inflicted by ROS on cellular and extracellular targets such as membrane lipids, proteins, and DNA clearly contributes to tissue and organ dysfunction in many pathological states. In particular, the oxidation of low-density lipoproteins (LDL) in the vascular wall is widely accepted to play a fundamental role in the pathogenesis of atherosclerosis (5, 40, 44, 56). It stands to reason, then, that antioxidants should be beneficial in preventing atherosclerosis and its complications in humans. Indeed, observational and epidemiological studies, although unable to establish a cause-and-effect relationship, suggest that increased dietary intake of naturally occurring antioxidant vitamins is associated with lower risk of cardiovascular disease (7, 8, 22, 24, 26, 39, 43, 46).

Why, then, have primary and secondary prevention trials of antioxidant regimens yielded less than encouraging results (14, 21, 32, 37, 45, 51, 57)? Some trials have been criticized because of insufficient dosing regimens or durations of antioxidant therapy, harmful interactions between the antioxidant agents, and flaws in enrolling or excluding subsets of patients, among other factors. Nevertheless, these simple explanations do not explain the negative results of all carefully conducted trials. The lack of proven benefit of antioxidants, in conjunction with a recently described detrimental effect on lipid metabolism (4), has led some to suggest that the use of supplemental antioxidant vitamins could even be hazardous to patients who are taking lipid-lowering medications (25).

The apparent lack of efficacy of supplemental antioxidant vitamins to prevent atherosclerosis in humans should be noteworthy not only to clinicians and patients but also to scientists who study the basic mechanisms of vascular disease. In this regard, we discuss several concepts that have emerged from the "antioxidant paradox" that might provide insight into the role of ROS in the pathogenesis of atherosclerotic vascular disease and into the pitfalls of conventional antioxidant therapy.

	DIFFERENCES BETWEEN IN VITRO AND IN VIVO OXIDATION OF LDL

TOP INTRODUCTION DIFFERENCES BETWEEN IN VITRO... CELLULAR AND ENZYMATIC SOURCES... EFFECTS OF ROS ON... IMPORTANCE OF ROS AS... ADDITIONAL CONSIDERATIONS CONCLUSIONS REFERENCES

Studies performed in vitro suggest that LDL particles are resistant to oxidation by Cu²⁺ until -tocopherol is consumed, in keeping with the putative function of vitamin E as a chain-breaking antioxidant (9). Tocopherol radicals formed during Cu²⁺-induced LDL oxidation can react with each other or with lipid peroxyl radicals, thereby yielding nonradical products and effectively terminating the peroxidation process. Alternatively, the tocopherol radicals can be scavenged by vitamin C, resulting in regeneration of -tocopherol. How can it be, then, that substantial amounts of oxidized lipids are present together along with relatively large amounts of -tocopherol and ascorbate in human atherosclerotic lesions (47)? One possibility is that under some circumstances (for example, at low radical fluxes in the absence of co-antioxidants), vitamin E could promote, rather than terminate, lipid peroxidation in LDL particles (reviewed in Ref. 53). Whether or not tocopherol-mediated peroxidation actually occurs in vivo, however, remains to be demonstrated. Alternatively, the ROS that oxidize LDL in vivo may not be efficiently scavenged by vitamin E.

	CELLULAR AND ENZYMATIC SOURCES OF ROS IN VASCULATURE

TOP INTRODUCTION DIFFERENCES BETWEEN IN VITRO... CELLULAR AND ENZYMATIC SOURCES... EFFECTS OF ROS ON... IMPORTANCE OF ROS AS... ADDITIONAL CONSIDERATIONS CONCLUSIONS REFERENCES

Figure 1 shows some of the key mechanisms of ROS formation, interaction, and degradation within the vasculature. Vascular ROS formation is, in large part, initiated by the one-electron reduction of molecular O₂ to O·, the production of which is increased in atherosclerosis (30, 31, 55). Potential cellular sources of O· in blood vessels include infiltrating phagocytic cells, which contain the high-capacity O·-generating flavoenzyme NADPH oxidase, as well as vascular endothelial cells, smooth muscle cells (SMC), and fibroblasts. An earlier report suggested that endothelial cells may be responsible for the increased production of O· in hypercholesterolemic blood vessels (31). Using confocal microscopy to examine the cellular localization of O· in situ, Miller et al. (29) demonstrated that SMC are a major source of ROS in blood vessels from atherosclerotic rabbits. Similar studies also suggest that much of the O· in atherosclerotic human coronary arteries is contained in the media and adventitia, where it is presumably generated by SMC and fibroblasts (Fig. 2).

View larger version (42K): [in this window] [in a new window]   Fig. 1.   Potential enzymatic sources of radical oxygen species (ROS) production in the vasculature and the locations (cytoplasmic, mitochondrial, or peroxisomal) of some of the important endogenous antioxidant enzymes. NAD(P)H, reduced nicotinamide adenine dinucleotide phosphate; NO, nitric oxide; MPO, myeloperoxidase; SOD, superoxide dismutase; EcSOD, extracellular SOD; MnSOD, manganese SOD; Cu/ZnSOD, copper/zinc SOD.

View larger version (61K): [in this window] [in a new window]   Fig. 2.   Examination of O· in situ in human blood vessels by confocal microscopy. Segments of coronary arteries were removed from freshly explanted hearts. Frozen sections of the vessel segments were incubated with dihydroethidium (HE; fluorescent probe that specifically reacts with O·) and examined by confocal scanning microscopy, as previously described (29). The coronary artery shown at left was obtained from a 42-yr-old woman with dilated cardiomyopathy. Note the lack of plaque formation, indicating the absence of significant atherosclerosis. The coronary arterial endothelium (E), media (M), and adventitia (A) exhibit uniformly low levels of red fluorescence of HE. The coronary artery shown at right was from a 69-yr-old man with atherosclerosis (note the large plaque within the subendothelial layer). Marked HE fluorescence is observed, particularly within the media and adventitia. The figures shown were obtained using identical conditions and laser settings and are representative of multiple arterial sections.

It was shown recently that a nonphagocytic NAD(P)H oxidase is a major source of ROS in cultured vascular cells (15-17), although xanthine oxidase, nitric oxide synthase, cytochrome P-450, and the mitochondrial electron transport chain may be important sources of ROS in specific situations. Oxidization of LDL by endothelial cells in vitro can be attenuated by overexpressing superoxide dismutase (SOD) in the cells, suggesting a role for O· and/or its reaction products in this process (10). On the other hand, although vitamin E rapidly reacts with lipid peroxyl radicals, it does not efficiently scavenge O·. Moreover, the localization of ROS within the deep layers of the blood vessel wall suggests that even if antioxidant vitamins were efficient scavengers of O·, delivery to sites where they are most needed may be problematic.

O· that exits from, or is produced outside of, vascular cells can be converted by extracellular SOD (ECSOD) to H₂O₂. In addition, O· produced within cells is converted by Cu/Zn SOD and Mn SOD to H₂O₂, which can readily cross cellular membranes. H₂O₂ present in the extracellular space is, in turn, converted to the highly reactive species HOCl by the enzyme myeloperoxidase (Fig. 1). Recent studies suggest that myeloperoxidase is localized to phagocytic cells in human atherosclerotic lesions (13, 48). Moreover, analysis of amino acid oxidation products in LDL isolated from the human arterial wall suggests that HOCl is an important modifier of LDL in vivo (20). In vitro, HOCl reacts rapidly with apolipoproteins in LDL, yielding secondary reaction products, such as chloramines, that induce lipid peroxidation (18). Additionally, myeloperoxidase converts L-tyrosine to tyrosyl radical, which can also induce lipid peroxidation in LDL particles (41). Interestingly, in vitro, vitamin E failed to protect LDL against protein oxidation by myeloperoxidase, and the HOCl-induced secondary lipid peroxidation proceeded less rapidly when the lipoproteins were depleted of -tocopherol (18, 19). These studies suggest that vitamin E may not afford protection against myeloperoxidase-dependent oxidative modification of LDL.

Another ROS implicated in the oxidation of LDL in vivo is peroxynitrite (OONO), the reaction product of O· and nitric oxide (20). In vitro, OONO-induced protein oxidation was found to be independent of the content of -tocopherol in LDL particles (52). Moreover, the magnitude of OONO-induced lipid peroxidation was increased with increasing -tocopherol content at oxidant-to-LDL ratios of <100:1 (52). Thus vitamin E also may not adequately protect against LDL oxidation by OONO, an important oxidant species in the blood vessel wall.

	EFFECTS OF ROS ON VASCULAR FUNCTION

TOP INTRODUCTION DIFFERENCES BETWEEN IN VITRO... CELLULAR AND ENZYMATIC SOURCES... EFFECTS OF ROS ON... IMPORTANCE OF ROS AS... ADDITIONAL CONSIDERATIONS CONCLUSIONS REFERENCES

The reaction between O· and nitric oxide also leads to diminished endothelium-dependent relaxation, a well-known feature of atherosclerosis (12). One very important contributing factor appears to be that the production of O· is increased in atherosclerosis (30, 31, 55). In this regard, the NAD(P)H oxidase in vascular cells is activated by cytokines thought to participate in atherosclerosis, such as platelet-derived growth factor (PDGF), angiotensin II, and thrombin (16, 17). Moreover, the activity of NAD(P)H oxidase is upregulated in experimental models of atherosclerosis, hypertension, and balloon denudation, suggesting that increased production of ROS via this pathway may represent a generalized response to vascular injury (1, 16, 17, 29, 34, 42). Not only would reaction of nitric oxide with O· generate the toxic species OONO and attenuate endothelium-dependent vasorelaxation, but it would also offset the beneficial effects of nitric oxide to inhibit platelet function, leukocyte adhesion, and SMC proliferation, among others. Wagner et al. (54) recently reported that inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase diminished endothelial O· production by preventing the isoprenylation of p21 rac, a small G protein that is an obligate component of NAD(P)H oxidase. This finding may help to explain some of the non-lipid-lowering beneficial effects of HMG-CoA reductase inhibitors on vascular function (6). Likewise, angiotensin II stimulates NAD(P)H oxidase expression and activity (15, 33), and angiotensin-1 receptor inhibition reduced O· production, improved endothelial dysfunction, and diminished plaque formation in hypercholesterolemic rabbits (55). On the other hand, clinical studies of vitamin E in humans have shown mixed results in regard to improvement in endothelial function in patients with atherosclerosis (reviewed in Ref. 3). Thus, if improvement in endothelial function is important in preventing atherosclerosis and its complications, treatment with vitamin E alone may be of little value. The beneficial effects of vitamin C on endothelial function are more consistent, however, which supports the view that coadministration of vitamin C with vitamin E is likely to be more efficacious (3, 28).

	IMPORTANCE OF ROS AS SIGNALING MOLECULES IN VASCULATURE

TOP INTRODUCTION DIFFERENCES BETWEEN IN VITRO... CELLULAR AND ENZYMATIC SOURCES... EFFECTS OF ROS ON... IMPORTANCE OF ROS AS... ADDITIONAL CONSIDERATIONS CONCLUSIONS REFERENCES

Traditionally, high levels of ROS have been viewed principally as toxic mediators of cell and tissue injury. More recently, however, low levels of ROS have been identified as important regulators of cellular signaling pathways and gene expression in the vasculature. For example, ROS can induce the release of arachidonic acid (2) and activate tyrosine kinases and mitogen-activated protein kinases (16), which are critical components of many intracellular signaling cascades, including those required for cell survival and growth (36, 49). In addition, many cardiovascular genes are redox sensitive. Redox regulation of gene expression occurs through multiple mechanisms, including activation of upstream signal transduction pathways and modulation of transcription factor binding activity (16). As ROS, nitric oxide, and products formed via interactions among oxidant species (including H₂O₂) can mediate signal transduction, it is conceivable that very high doses of antioxidants could, paradoxically, produce harmful effects on cellular signaling processes. In addition, the expression of antioxidant enzymes is upregulated in disease states and by factors such as angiotensin II and tumor necrosis factor-, indicative of an adaptive response to oxidative stress (50). By altering redox-mediated signaling, it is possible that antioxidant therapy could suppress this adaptive response, which may, paradoxically, increase the vulnerability of the blood vessel to oxidative injury.

	ADDITIONAL CONSIDERATIONS

TOP INTRODUCTION DIFFERENCES BETWEEN IN VITRO... CELLULAR AND ENZYMATIC SOURCES... EFFECTS OF ROS ON... IMPORTANCE OF ROS AS... ADDITIONAL CONSIDERATIONS CONCLUSIONS REFERENCES

The aforementioned potential pitfalls of antioxidant therapy might be considered theoretical rather than pragmatic. Several other more practical considerations should be mentioned. First, although antioxidants are typically given in constant amounts and dosing intervals, oxidative stress is not a continuous, uniform process. For example, marked intensification of oxidative stress occurs transiently after vascular balloon injury, and, most likely, during periods of increased inflammatory activity in atherosclerotic lesions (1). The oxidants may activate signaling cascades and gene expression that, once set in motion, no longer require the presence of ROS. This may explain why antioxidant therapy must be given before balloon angioplasty to be effective (1).

Ideally, antioxidant therapies should be judged on the basis of their therapeutic efficacy. Unfortunately, determination of the efficacy of antioxidant therapy is hampered by the lack of available methodology to quantify ROS in tissues and blood vessels in vivo. Surrogate end points, such as assessment of endothelial function or lipid peroxidation products in the plasma, do not adequately reflect the capacity of antioxidants to protect the deeper layers of the blood vessel wall from oxidative injury. Negative results of clinical trials must be interpreted cautiously in the absence of verification that antioxidant therapy successfully reduces vascular oxidant stress.

Antioxidant defense systems are preferentially localized to specific subcellular domains (Fig. 1). The lipophilic vitamin E is partitioned into cell membranes and may not adequately protect against oxidant stress in the aqueous cytosolic environment. Furthermore, vitamin E has eight diastereoisomers, which vary considerably in regards to bioavailability and antioxidant potency. Surprisingly, many clinical studies do not specify which isomer (or mixture of isomers) was administered to patients. Some of the stereoisomers possess important actions aside from their chain-breaking antioxidant effects, such as inhibition of protein kinase C, which could affect vascular function, and, perhaps, O· production (11, 23). This may explain why studies involving dietary sources of vitamin E are more encouraging than studies using a single isomer.

It is important to consider that antioxidants do not inhibit the production of ROS. Conceptually, agents that inhibit oxidant production should be much more effective than scavenger agents (i.e., antioxidant vitamins) in ameliorating oxidative stress. This is highlighted by the finding that the rate of reaction of ROS with antioxidant vitamins is orders of magnitude slower than with other cellular targets. Inhibiting ROS production would be the surest way of preventing oxidant species from inflicting cellular damage. In this regard, the NAD(P)H oxidase of vascular cells, which appears to a major producer of ROS in vascular diseases, may be a novel therapeutic target for vascular research.

Finally, oxidative stress may contribute to vascular diseases only in certain subsets of patients. This possibility is suggested by studies in experimental models of hypertension (27, 35). Genetic polymorphisms in ROS-generating systems or cellular antioxidants may identify subsets of patients who are most prone to oxidative stress. Identification of such at-risk patients would facilitate clinical studies designed to determine whether they might benefit from antioxidant therapy.

	CONCLUSIONS

TOP INTRODUCTION DIFFERENCES BETWEEN IN VITRO... CELLULAR AND ENZYMATIC SOURCES... EFFECTS OF ROS ON... IMPORTANCE OF ROS AS... ADDITIONAL CONSIDERATIONS CONCLUSIONS REFERENCES

The recognition that supplementation with antioxidant vitamins (in particular, vitamin E) is of little or no benefit in preventing or treating atherosclerosis in large-scale clinical studies in humans raises more questions than it answers. On the one hand, there is ample experimental evidence that ROS play a pivotal role in the pathogenesis of atherosclerotic vascular disease. However, the ROS responsible for in vivo oxidation of LDL, a key factor in the development of atherosclerosis, may not be effectively scavenged by vitamin E. Also, the cellular actions of ROS are quite complex, in that low levels of ROS appear to be essential for cellular signaling. Thus antioxidant supplementation could potentially be harmful to those tissues that are not subjected to substantial oxidative stress. Conversely, for those disorders that are associated with marked increases in ROS production, such as vascular balloon injury, the temporal and spatial characteristics of oxidant production pose great challenges in regard to delivering effective antioxidant therapy. In addition, the methods currently available to assess the degree of oxidative stress, and the efficacy of antioxidant therapy, in vivo are quite limited. Finally, ROS may participate only in certain subsets of vascular diseases and/or in specific patient subpopulations. Thus the recent "negative" trials of antioxidant therapy for atherosclerosis should herald a new beginning, rather than an end, for basic research into the role of ROS in vascular diseases.

	ACKNOWLEDGEMENTS

This work was supported by National Heart, Lung, and Blood Institute Grants HL-49264 (to N. L. Weintraub) and HL-62984 (to F. J. Miller, Jr., and N. L. Weintraub) and by an American Heart Association grant-in-aid (to W.-G. Li).

	FOOTNOTES

Address for reprint requests and other correspondence: N. L. Weintraub, Dept. of Internal Medicine, Cardiovascular Division, Univ. of Iowa, 200 Hawkins Dr., E329-GH, Iowa City, IA 52242 (E-mail: neal-weintraub{at}uiowa.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

	REFERENCES

TOP INTRODUCTION DIFFERENCES BETWEEN IN VITRO... CELLULAR AND ENZYMATIC SOURCES... EFFECTS OF ROS ON... IMPORTANCE OF ROS AS... ADDITIONAL CONSIDERATIONS CONCLUSIONS REFERENCES

1.   Azevedo, LCP, Pedro MA, Souza LC, Souza HP, Janiszwski M, Protasio LL, and Laurindo FRM Oxidative stress as a signaling mechanism of the vascular response to injury: the redox hypothesis of restenosis. Cardiovasc Res 47: 436-445, 2000[Abstract/Free Full Text].

2.   Cane, A, Bretion M, Koumanov K, Bereziat G, and Colard O. Oxidant-induced arachidonic acid release and impairment of fatty acid acylation in vascular smooth muscle cells. Am J Physiol Cell Physiol 274: C1040-C1046, 1998[Abstract/Free Full Text].

3.   Carr, AC, Zhu BZ, and Frei B. Potential antiatherogenic mechanisms of ascorbate (vitamin C) and -tocopherol (vitamin E). Circ Res 87: 349-354, 2000[Abstract/Free Full Text].

4.   Cheung, MC, Zhao XQ, Chait A, Albers JJ, and Brown BG. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 21: 1320-1326, 2001[Abstract/Free Full Text].

5.   Chisolm, GM, III, Hazen SL, Fox PL, and Cathcart MK. The oxidation of lipoproteins by monocytes-macrophages: biochemical and biological mechanisms. J Biol Chem 274: 25959-25962, 1999[Free Full Text].

6.   Dupuis, J, Tardif JC, Cernacek P, and Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation 99: 3227-3233, 1999[Abstract/Free Full Text].

7.   Emmert, DH, and Kirchner JT. The role of vitamin E in the prevention of heart disease. Arch Fam Med 8: 537-542, 1999[Abstract/Free Full Text].

8.   Enstrom, JE, Kanim LE, and Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 3: 194-202, 1992[ISI][Medline].

9.   Esterbauer, H, Striegl G, Puhl H, and Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 6: 67-75, 1989[ISI][Medline].

10.   Fang, X, Weintraub NL, Rios CD, Chappell DA, Zwacka RM, Engelhardt JF, Oberley LW, Yan T, Heistad DD, and Spector AA. Overexpression of human superoxide dismutase inhibits oxidation of low-density lipoprotein by endothelial cells. Circ Res 82: 1289-1297, 1998[Abstract/Free Full Text].

11.   Freedman, JE, Li L, Sauter R, and Keaney JF, Jr. -Tocopherol and protein kinase C inhibition enhance platelet-derived nitric oxide release. FASEB J 14: 2377-2379, 2000[Free Full Text].

12.   Freiman, PC, Mitchell GC, Heistad DD, Armstrong ML, and Harrison DG. Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ Res 58: 783-789, 1986[Abstract/Free Full Text].

13.   Fu, X, Kassim SY, Parks WC, and Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7): a mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 276: 41279-41287, 2001[Abstract/Free Full Text].

14.   GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354: 447-455, 1999[ISI][Medline].

15.   Griendling, KK, Minieri CA, Ollerenshaw JD, and Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994[Abstract/Free Full Text].

16.   Griendling, KK, Sorescu D, Lassegue B, and Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20: 2175-2183, 2000[Abstract/Free Full Text].

17.   Griendling, KK, Sorescu D, and Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86: 494-501, 2000[Abstract/Free Full Text].

18.   Hazell, LJ, Davies MJ, and Stocker R. Secondary radicals derived from chloramines of apolipoprotein B-100 contribute to HOCl-induced lipid peroxidation of low-density lipoproteins. Biochem J 339: 489-495, 1999.

19.   Hazell, LJ, and Stocker R. -Tocopherol does not inhibit hypochlorite-induced oxidation of apolipoprotein B-100 of low-density lipoprotein. FEBS Lett 414: 541-544, 1997[ISI][Medline].

20.   Heinecke, JW. Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human arterial wall. FASEB J 13: 1113-1120, 1999[Abstract/Free Full Text].

21.   Hennekens, CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, and Peto R. Lack of effect of long-term supplementation with  carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334: 1145-1149, 1996[Abstract/Free Full Text].

22.   Jacobs, DR, Jr, Meyer KA, Kushi LH, and Folsom AR. Whole grain intake may reduce the risk of ischemic heart disease death in postmenopausal women: the Iowa Women's Health Study. Am J Clin Nutr 68: 248-257, 1998[Abstract].

23.   Keaney, FJ, Jr, Guo Y, Cunningham D, Shwaery GT, Xu A, and Vita JA. Vascular incorporation of -tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation. J Clin Invest 98: 386-394, 1996[ISI][Medline].

24.   Kritchevsky, SB, Tell GS, Shimakawa T, Dennis B, Li R, Kohlmeier L, and Heiss G. Provitamin A carotinoid intake and carotid artery plaques: the Atherosclerosis in Communities Study. Am J Clin Nutr 68: 726-733, 1998[Abstract].

25.   Kuller, LH. A time to stop prescribing antioxidant vitamins to prevent and treat heart disease? Arterioscler Thromb Vasc Biol 21: 1253-1255, 2001[Free Full Text].

26.   Kushi, LH, Folsom AR, Prieas RJ, Mink PJ, Wu Y, and Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 334: 1156-1162, 1996[Abstract/Free Full Text].

27.   Laursen, JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, and Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 95: 588-593, 1997[Abstract/Free Full Text].

28.   Levine, GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF, Jr, and Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 96: 1107-1113, 1996[ISI].

29.   Miller, FJ, Jr, Gutterman DD, Rios CD, Heistad DD, and Davidson BL. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 82: 1298-1305, 1998[Abstract/Free Full Text].

30.   Nunes, GL, Robinson K, Kalynych A, King SB, III, Sgoutas DS, and Berk CB. Vitamins C and E inhibit superoxide production in the pig coronary artery. Circulation 96: 3593-3601, 1997[Abstract/Free Full Text].

31.   Ohara, Y, Peterson TE, and Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91: 2546-2551, 1993.

32.   Omenn, GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, and Hammar S. Effects of a combination of  carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334: 1150-1155, 1996[Abstract/Free Full Text].

33.   Pagano, PJ, Chanock SJ, Siwik DA, Colucci WS, and Clark JK. Angiotensin II induces p67phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts. Hypertension 32: 331-337, 1998[Abstract/Free Full Text].

34.   Pagano, PJ, Clark CK, Cifuentes-Pagano ME, Clark SM, Callis GM, and Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci USA 94: 14483-14488, 1997[Abstract/Free Full Text].

35.   Rajagopalan, S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, and Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest 97: 1916-1923, 1996[ISI][Medline].

36.   Rao, GN, and Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 70: 593-599, 1992[Abstract/Free Full Text].

37.   Rapola, JM, Viratimo J, Ripatti S, Huttunen JK, Albanes D, Taykor PR, and Heinonen OP. Randomized trial of -tocopherol and -carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 349: 1715-1720, 1997[ISI][Medline].

38.   Rice-Evans, CA, and Burdon RH. Free Radical Damage and Its Control. Amsterdam: Elsevier, 1994, p. 25-27.

39.   Rimm, EB, Stampfer MJ, and Ascherio A. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 328: 1450-1456, 1993[Abstract/Free Full Text].

40.   Ross, R. A pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993[Medline].

41.   Savenkova, MI, Mueller DM, and Heinecke JW. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J Biol Chem 269: 20394-20400, 1994[Abstract/Free Full Text].

42.   Souza, HP, Souza LC, Anastacio VM, Pereira AC, Junqueira de L M, Krieger JE, da Luz PL, Augusto O, and Laurindo FRM Vascular oxidant stress early after balloon injury: evidence for increased NAD(P)H oxidoreductase activity. Free Radic Biol Med 28: 1232-1242, 2000[ISI][Medline].

43.   Stampfer, MJ, Hennekens CH, and Manson JE. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 328: 14444-14449, 1993.

44.   Steinberg, D, Parthasarathy S, Carew TE, Khoo JC, and Witzum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-924, 1989[ISI][Medline].

45.   Stephens, NG, Parsons A, and Schofield PM. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347: 781-786, 1996[ISI][Medline].

46.   Street, DA, Comstock GW, Salkeld RM, Schep W, and Klag MJ. Serum antioxidants and myocardial infarction. Are low levels of carotenoids and -tocopherol risk factors for myocardial infarction? Circulation 90: 1154-1161, 1994[Abstract/Free Full Text].

47.   Suarna, C, Dean RT, May J, and Stocker R. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of -tocopherol and ascorbate. Arterioscler Thromb Vasc Biol 15: 1616-1624, 1995[Abstract/Free Full Text].

48.   Sugiyama, S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, and Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 158: 879-891, 2001[Abstract/Free Full Text].

49.   Sundaresan, M, Yu ZX, Ferrans VJ, Irani K, and Finkel T. Requirement for generation of H₂O₂ for platelet-derived growth factor signal transduction. Science 270: 296-299, 1995[Abstract/Free Full Text].

50.   Suziki, K, Tatsumi H, Satoh S, Senda T, Nakata T, Jujii J, and Taniguchi N. Manganese-superoxide dismutase in endothelial cells: localization and mechanism of induction. Am J Physiol Heart Circ Physiol 265: H1173-H1178, 1993[Abstract/Free Full Text].

51.   The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. The effect of vitamin E and -carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330: 1029-1035, 1994[Abstract/Free Full Text].

52.   Thomas, SR, Davies MJ, and Stocker R. Oxidation and antioxidation of human low-density lipoprotein and plasma exposed to 3-morpholinosydnonimine and reagent peroxynitrite. Chem Res Toxicol 11: 484-494, 1998[ISI][Medline].

53.   Thomas, SR, and Stocker R. Molecular action of vitamin E in lipoprotein oxidation: implications for atherosclerosis. Free Radic Biol Med 28: 1795-1805, 2000[ISI][Medline].

54.   Wagner, AH, Kohler T, Ruckschloss U, Just I, and Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20: 61-69, 2000[Abstract/Free Full Text].

55.   Warnholtz, A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Bohm M, Meinertz T, and Munzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 99: 2027-2033, 1999[Abstract/Free Full Text].

56.   Witzum, JL, and Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88: 1785-1792, 1991.

57.   Yusuf, S, Sleight P, Pogue J, Bosch J, Davies R, and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145-153, 2000[Abstract/Free Full Text].